The Center for Military Precision Health (CMPH) conducts innovative research, applying genomic science, discoveries, and precision techniques to enhance the health, readiness, and well-being of the warfighter and the DoD beneficiary community.


By the end of 2024, CMPH will be a central hub for collaborative genomics research, education, and treatment in military medicine. CMPH will be a CLIA-certified and CAP-accredited organization: capable, accurate, informative, and secure for personalized genetics-based care and genomics studies in military populations.

What We Do

CMPH provides standardized genome profiling services, genomic data analysis, and genomic data storage under DoD security and privacy policies, addressing eight DoD requirements across the Military Health System (MHS). Current research topics include obesity prevention, cardiovascular consequences of traumatic brain injury, and genomic risks for cancer and severe COVID infection.



Genomic and transcriptomic profiling on over 150,000 samples


CMPH addresses eight separate DoD requirements across the MHS


5,400 Midshipmen screened for asymptomatic cardiovascular disease


Using novel screening methods, 12 minutes is the average screening time for asymptomatic cardiovascular screening

Recent Deliverables

Cardiovascular Screening
of USNA Recruits

In response to two sudden cardiac deaths (SCD) and one life-threatening cardiac syncope at the US Naval Academy, CMPH/MICOR scientists implemented a practical screening program to reduce SCD.

Precision Medicine Special Issue, Military Medicine

CMPH scientists served as guest editors in creation of a special edition of Military Medicine focused on Precision Health


American Genome Center Sequencing Satellite Location at AFRRI

The satellite sequencing location at the Armed Forces Radiobiology Research Institute has validated capabilities to conduct small-scale next-generation sequencing activities using the Illumina NextSeq 500.

Personalized Characterization of AML Clonal Architecture

CMPH analyzed tumor whole-genome sequencing for exact DNA structural breakpoints in AML driver genes to develop patient-specific primers.